We exist for
...facilitating opportunities in health management, which improve quality and length of human life in any location on the globe using cutting edge technologies that generate more data about health enhancing foundation for new knowledge and opportunities. We always act in the interests of health. The results of our work develop the culture of health care.
We strive to
….become a major international strategic investor in digital health in just five years. Although we do financial transactions, our main focus is on creating valuable agenda for the international digital healthcare community and building a sustainable ecosystem for development of people in Medme and its portfolio companies.
The growth effort of the company in 2016-2017 is focused on the clusters of Bordeaux, Turin and Wroclaw in addition to the domestic market.
The strategic planning horizon of Medme is usually longer and the requirements towards the practical outcome of the business models are much higher.
The process of selection of the target companies has distinctions defined by the company’s mission, vision and strategy:
We invest and collaborate to grow businesses
We are looking for sustainable business models, which work today, have clear options for tomorrow and realistic scenarios for 5-10 years horizon. We manage risks not by multiple stakes on different players, but through deep judgement about the industry.
In the high potential market segments
We build synergetic businesses in the markets, which are global and have 100+ billion dollar potential within next 10 years. We apply permanent effort to maintain an actual model of global healthcare industry as well as its different segments in their dynamics.
Built by solid ambitious teams
We plan to grow and mature with the start-ups that we invest. So, we are focused on people with significant global ambitions and motivation for the rapid and endless development of their skills and knowledge, open to change and hard work.
Under current policies we do not invest in medical devices and drug development.